From another MB (WatsonH):
Ideas and probabilities
.
Ok, I am posting after the stock went up, before someone says I move the market. I can't be blamed for everything. Someone mentioned Ihub, I have no interest in posting there, they would block me in seconds. Yahoo already has issued warnings on dismissal of account. Novartis will be at Rodman for AMBS, second to that, expect diabetes info to be released soon after prep and review (I'd guess three weeks max). Call it a courting process as I believe some in the south may say, no pharma will come right in and buy the company as a whole. Look for licensing and royalties off of the platform. Look for Lympro far sooner than end of q3, validation has to be done soon with timing on when it started. There could be a validation announcement with a BD agreement, why, BD has stock, too. Better for all to benefit, rather than just one. After Rodman, expect new analysts, two are there that I am aware of to review the company, also expect a higher target. Fidelity bio-sector will be there scheduled at conference, very good for AMBS, they tend to spend far more in bio that most funds. The financing announcement of 18 months sustained cash is important. It's simple leverage. All mostly baby steps, but every baby step is huge when you're still learning to walk. Stable, slow and methodical will win this race, not massive news all at once. Tempered approaches are key for Gerald to catch the right attention for the right price, he not only has shareholders to please, including himself, he has a product to move forward. Is he looking at 50m or 50b? You should get what I am saying with that statement, MANF has a lot of work to do. Should be a fun next few weeks for everyone. I reiterate, these are my thoughts and projections, they are not a signal to buy, sell or do anything you wouldn't normally do on your own. Less
